Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-02: Sigvotatug vedotin plus pembrolizumab versus pembrolizumab alone as first-line treatment for PD-L1-high advanced non-small cell lung cancer
CTR20253393Phase 3Active
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sigvotatug vedotin and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Started Oct 2025; status: active.
02
Drugs
sigvotatug vedotinpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253393.